Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Blood (2018)
  • William G. Wierda, University of Texas MD Anderson Cancer Center
  • Michael R. Bishop, University of Chicago
  • Olalekan O. Oluwole, Vanderbilt University
  • Aaron C. Logan, University of California, San Francisco
  • Maria R. Baer, University of Maryland, College Park
  • William B. Donnellan, Sarah Cannon Research Institute
  • Kristen M. O'Dwyer, University of Rochester Medical Center
  • Januario E. Castro, Mayo Clinic
  • Gary J. Schiller, University of California, Los Angeles
  • Houston Holmes, Texas Oncology
  • Mehrdad Abedi, University of California, Davis
  • Armin Ghobadi, Washington University in St. Louis
  • Martha L. Arellano, Emory University
  • Adriana K. Malone, Icahn School of Medicine at Mount Sinai
  • John M. Pagel, Fred Hutchinson Cancer Research Center
  • Armen Mardiros, Kite, a Gilead Company, Santa Monica, CA
  • Tong Shen, Kite, a Gilead Company, Santa Monica, CA
  • Remus Vezan, Kite, a Gilead Company, Santa Monica, CA
  • Rajul K. Jain, Kite, a Gilead Company, Santa Monica, CA
  • Bijal D. Shah, H. Lee Moffitt Cancer Center, Tampa, FL
Link
Disciplines
Publication Date
November 21, 2018
DOI
10.1182/blood-2018-99-111531
Citation Information
William G. Wierda, Michael R. Bishop, Olalekan O. Oluwole, Aaron C. Logan, et al.. "Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia" Blood Vol. 132 (2018) p. 897 - 897
Available at: http://works.bepress.com/john-pagel/292/